Brain

Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

SPC-15’s intranasal spray formulation meets safety standards for clinical trial development SARASOTA, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Silo...

Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).

This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted.DXVX is taking...

GoMo Health Launches the Women, Children and Families Engagement Hub to Improve Whole-Family Care and Health Outcomes In Every Life Stage

Holistic engagement programs offer healthcare organizations a scalable solution to support women and families in managing their physical, mental, and...

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial...

Invictus Foundation™ Receives Grant from CSX to Install a Behavioral Telehealth Platform in its Southeastern Regional Welcome Home Network and Continue the Capital Construction Planning for Eight Regional TBI & Behavioral Health Centers Across the Nation

error: Content is protected !!